文献速递淋巴瘤

血管内淋巴瘤的临床特征、预后指标与生存结局:梅奥诊所2003—2018年经验

Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003-2018).
PubMed 文献 · Am J Hematol · 2022-07-06

该回顾性分析纳入2003—2018年在梅奥诊所治疗的55例血管内淋巴瘤(IVL)患者,中位年龄68岁,64%为男性。最常见的首发症状为皮疹43%和体重下降30%。根据中枢神经系统(CNS)是否受累分为CNS-IVL(36.5%)和非CNS-IVL(63.5%)。整个队列估计5年无进展生存(PFS)率和总生存(OS)率分别为38.6%和52%。血小板计数<150×10^9/L、年龄>60岁及未接受利妥昔单抗治疗为不良预后因素。

要点

  • IVL最常见的首发症状为皮疹43%和体重下降30%。
  • 骨髓是最常见的诊断性活检部位,占45%。
  • 仅皮肤受累的IVL与极好生存相关。

核心结论

  • 整个队列估计5年PFS率为38.6%,估计5年OS率为52%。
  • 仅皮肤受累的IVL与极好生存相关。
  • 血小板计数<150×10^9/L、年龄>60岁及未接受利妥昔单抗治疗为不良预后因素。
  • 需要进一步研究以确定新的治疗方法。

研究设计与样本

  • 本研究为回顾性分析,纳入2003—2018年在梅奥诊所治疗的55例血管内淋巴瘤(IVL)患者。
  • 中位诊断年龄为68岁,64%为男性。

主要发现

  • 最常见的首发症状为皮疹43%和体重下降30%。
  • 有CNS受累的IVL患者中,脑MRI显示多灶性受累者占76%(13/17)。
  • 无CNS受累的IVL患者中,FDG-PET异常者89%(17/19)对高摄取病灶进行活检并获得明确诊断。
  • 最常见的诊断性活检部位为骨髓,占45%;56%的患者有多器官受累。
  • 根据CNS受累情况,36.5%(20/55)为CNS-IVL,63.5%(35/55)为非CNS-IVL。

关键数值与推荐

  • CNS-IVL组包括临床孤立性CNS受累(仅CNS IVL)22%(12/55)和临床CNS与周围部位混合受累(M-IVL)14.5%(8/55)。
  • 非CNS-IVL组包括临床孤立性皮肤受累(仅皮肤IVL)9%(5/55)和伴或不伴皮肤受累的周围型IVL(P-IVL)54.5%(30/55)。
  • 皮肤受累主要位于下肢。
  • 病理上,89%(48/54)为B细胞IVL。
  • CNS-IVL患者中75%(12/16)使用利妥昔单抗+大剂量甲氨蝶呤为基础的方案,非CNS-IVL患者中60%(17/28)使用RCHOP方案。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intravascular lymphoma (IVL) is a rare extranodal non-Hodgkin lymphoma. We performed a retrospective analysis of 55 IVL patients who were treated at our institution 2003-2018. Median age at diagnosis was 68 years, and 64% were males. The most frequent presenting symptoms were skin rash 43% and weight loss 30%. MRI brain on IVL patients with CNS involvement (CNS-IVL) showed multifocal involvement in 76% (13/17). 89% (17/19) of non-CNS-IVL patients with abnormal FDG-PET had biopsy of an avid lesion resulting in definitive diagnosis. The top diagnostic biopsy site was the bone marrow (45%). 56% had multiorgan involvement. Based on CNS involvement, 36.5% (20/55) had CNS-IVL and 63.5% (35/55) had non-CNS-IVL. CNS-IVL group consists of clinically isolated CNS involvement (CNS-only IVL) (22%;12/55) and mixed clinical CNS and peripheral site involvement (M-IVL) (14.5%; 8/55). Non-CNS-IVL group consists of clinically isolated skin involvement (skin-only IVL) (9%; 5/55) and peripheral IVL with or without skin involvement (P-IVL); (54.5%; 30/55). Skin involvement was predominantly in the lower extremities. Pathologically, 89% (48/54) were B-cell IVL. Rituximab + high-dose methotrexate-based regimen were used in 75% (12/16) of CNS-IVL patients and RCHOP in 60% (17/28) of non-CNS-IVL patients. Estimated 5-year progression free survival (PFS) and overall survival (OS) for the entire cohort were 38.6% and 52%, respectively. Skin-only IVL was associated with excellent survival. Platelet count <150x109 /L, age > 60Y, and treatment without Rituximab were poor prognostic factors. Further research is necessary to identify novel therapies.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Seegobin K, Li Z, Alhaj Moustafa M, et al. Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003-2018). Am J Hematol. 2022. PMID: 35713565. doi:10.1002/ajh.26635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。